Armata Pharmaceuticals, Inc. (ARMP)
3.135
+0.08
(+2.45%)
USD |
NYAM |
Oct 22, 10:11
Armata Pharmaceuticals EPS Diluted (Quarterly) : -0.272 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.272 |
| March 31, 2026 | -3.158 |
| December 31, 2025 | -3.42 |
| September 30, 2025 | -0.7363 |
| June 30, 2025 | -0.4502 |
| March 31, 2025 | -0.1805 |
| December 31, 2024 | 0.044 |
| September 30, 2024 | -0.1515 |
| June 30, 2024 | -0.2474 |
| March 31, 2024 | -0.6926 |
| December 31, 2023 | -0.5498 |
| September 30, 2023 | -0.8635 |
| June 30, 2023 | -0.0983 |
| March 31, 2023 | -0.402 |
| December 31, 2022 | -0.2861 |
| September 30, 2022 | -0.239 |
| June 30, 2022 | -0.256 |
| March 31, 2022 | -0.3026 |
| December 31, 2021 | -0.2299 |
| September 30, 2021 | -0.2183 |
| June 30, 2021 | -0.2501 |
| March 31, 2021 | -0.2686 |
| December 31, 2020 | -0.3596 |
| September 30, 2020 | -0.3136 |
| June 30, 2020 | -0.2567 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.4858 |
| December 31, 2019 | -0.4787 |
| September 30, 2019 | -0.7281 |
| June 30, 2019 | -0.6993 |
| March 31, 2019 | -11.25 |
| December 31, 2018 | -3.313 |
| September 30, 2018 | -8.338 |
| June 30, 2018 | -9.529 |
| March 31, 2018 | -3.299 |
| December 31, 2017 | -3.469 |
| September 30, 2017 | -1.229 |
| June 30, 2017 | -16.90 |
| March 31, 2017 | -27.09 |
| December 31, 2016 | -129.88 |
| September 30, 2016 | -44.80 |
| June 30, 2016 | -109.20 |
| March 31, 2016 | -114.80 |
| December 31, 2015 | -75.60 |
| September 30, 2015 | -42.00 |
| June 30, 2015 | 163.45 |
| March 31, 2015 | -489.99 |
| December 31, 2014 | -32.97 |
| September 30, 2014 | 23099.54 |
| June 30, 2014 | 279.99 |
| March 31, 2014 | -489.99 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 74.14M |
| Revenue (Quarterly) | 2.51M |
| Total Expenses (Quarterly) | -71.63M |
| Enterprise Value | 403.67M |
| Gross Profit Margin (Quarterly) | 76.45% |
| Earnings Yield | -242.0% |
| Normalized Earnings Yield | -135.63 |